TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal-Offspring Metabolics:Family Intervention Trial (MOMFIT)
Brief Summary: The prevalence of maternal overweight and obesity has nearly doubled in the United States since 1976. In 2004-2005, 42% of pregnant women had body mass index (BMI) above 25 versus 23% in 1993. Most American women are overweight/ obese (OW/OB) at conception, especially within certain racial, ethnic, and lower socioeconomic groups leading to increased adverse maternal and birth outcomes. This study will recruit, randomize and test in 300 ethnically diverse OW/OB pregnant women a behavioral intervention aimed at controlling gestational weight gain (GWG) through recommended diet, activity and lifestyle changes that are to be maintained postpartum. Outcomes include anthropometric (height, weight, percent body fat) metabolic (blood pressure, fasting glucose, insulin, HbA1c, lipids and C-reactive protein) and behavioral measures (diet. physical activity, sleep and stress). In addition, babies will be measured for length, weight and percent body fat. The goal is to limit excessive gestational weight gain through improved maternal lifestyle that can be maintained and modelled for the family post partum and beyond.


Options:
A: Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Arm Label: Lifestyle Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention Group | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention Group; Assigned to Arm(s): Lifestyle Intervention Group | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group
B: Arm Label: Enhanced Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced standard care | Arm Label: Intensive lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Enhanced standard care; Assigned to Arm(s): Enhanced Standard Care | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention
C: Arm Label: Lifestyle and nutrition control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle intervention group | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention group; Assigned to Arm(s): Lifestyle intervention group
D: Arm Label: Normative intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Normative Intervention | Arm Label: Routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Normative Intervention; Assigned to Arm(s): Normative intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long Term Follow-Up Study of the Safety and Exploratory Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
Brief Summary: This is a long term follow-up study of the open label, single-center, phase I clinical trial to evaluate the safety of Pneumostem® in premature infants with BPD.


Options:
A: Arm Label: infusions; Type: EXPERIMENTAL; Interventions: Biological: infusion of autologous cord blood | Arm Label: historical control; Type: OTHER; Interventions: Other: Neurodevelopmental outcomes | Intervention Type: BIOLOGICAL; Name: infusion of autologous cord blood; Assigned to Arm(s): infusions | Intervention Type: OTHER; Name: Neurodevelopmental outcomes; Assigned to Arm(s): historical control
B: Arm Label: Registry Cohort; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Registry Cohort
C: Arm Label: Registry Cohort; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Registry Cohort
D: Arm Label: Pneumostem®; Type: N/A; Interventions: Biological: Pneumostem® | Intervention Type: BIOLOGICAL; Name: Pneumostem®; Assigned to Arm(s): Pneumostem®

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Brief Summary: The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS


Options:
A: Arm Label: fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: fingolimod 0.25mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: glatiramer acetate 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate | Intervention Type: DRUG; Name: fingolimod; Assigned to Arm(s): fingolimod 0.25mg, fingolimod 0.5 mg | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): glatiramer acetate 20 mg
B: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod 0.5 mg, Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Part I Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part I BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Arm Label: Part II BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part I Placebo | Intervention Type: DRUG; Name: dimethyl fumarate; Assigned to Arm(s): Part I BG00012, Part II BG00012

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does CMV Reactivation Cause Functional Impairment of CMV Specific CD4+ T-cells? The Potential for Valaciclovir to Prevent CMV-mediated Adverse Modulation of the Immune System in Patients With ANCA-associated Vasculitis
Brief Summary: The purpose of this study is to determine whether Cytomegalovirus (CMV) reactivation in ANCA-associated vasculitis (AAV) patients can be effectively and safely reduced using an antiviral agent (valaciclovir) and whether this in turn improves the function of the immune system thereby also improving the body's ability to fight other infections.

The primary hypothesis is that repeated episodes of CMV reactivation in AAV patients drive the expansion and functional impairment of CMV-specific T-cells, with increased susceptibility to infection. Inhibition of CMV replication with valaciclovir will block further stimulation of CMV specific T-cells and increase the functional capacity of the immune system.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Plasma exchange | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous methyl prednisolone, Drug: Methyl prednisolone | Intervention Type: PROCEDURE; Name: Plasma exchange; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Intravenous methyl prednisolone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methyl prednisolone; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): 2
C: Arm Label: Placebo plus azathioprine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Azathioprine | Arm Label: Belimumab 10 mg/kg plus azathioprine; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 10 mg/kg, Drug: Azathioprine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo plus azathioprine | Intervention Type: BIOLOGICAL; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg plus azathioprine | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Belimumab 10 mg/kg plus azathioprine, Placebo plus azathioprine
D: Arm Label: Valaciclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valaciclovir | Arm Label: No additional treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Valaciclovir; Assigned to Arm(s): Valaciclovir

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Advanced Mechanical Circulatory Support in Patients With ST Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock. The Danish Cardiogenic Shock Trial
Brief Summary: Cardiogenic shock a serious complication of a heart attack (myocardial infarction). Despite rapid invasive treatment, circulatory support using positive inotropes and mechanical support with intra-aortic balloon counterpulsation (IABP), and evaluation of several new treatments during the last decade, the mortality in patients with cardiogenic shock still exceeds 50%. An alternative to current management is restoration of the volume of blood pumped by the heart (cardiac output) using a ventricular assist device. In the acute setting this is difficult but can be done using the Impella device which is a catheter-based, axial flow pump that pumps blood directly from the left ventricle into the circulation thereby restoring blood flow to the failing organs. In 2012 a more powerful Impella has been introduced that is able to deliver 3.5l/min (approximately 75% of a normal cardiac output). The hypothesis of the current study is to reduce mortality and morbidity of patients with cardiogenic shock using the Impella CP. The study will be carried out as a randomized multicenter study where eligible patients will be randomized to receive conventional circulatory support or support with the Impella device and inotropic support if needed. A total of 360 patients are planned to be enrolled, and the primary endpoint will be death.


Options:
A: Arm Label: Conventional circulatory support; Type: PLACEBO_COMPARATOR; Interventions: Device: Conventional circulatory support | Arm Label: Impella; Type: ACTIVE_COMPARATOR; Interventions: Device: Impella CP | Intervention Type: DEVICE; Name: Conventional circulatory support; Assigned to Arm(s): Conventional circulatory support | Intervention Type: DEVICE; Name: Impella CP; Assigned to Arm(s): Impella
B: Arm Label: Control arm of study; Type: NO_INTERVENTION; Interventions: Device: Counterpulsation with IAB | Intervention Type: DEVICE; Name: Counterpulsation with IAB; Assigned to Arm(s): Control arm of study
C: Arm Label: Extra-Corporal Life Support (ECLS); Type: ACTIVE_COMPARATOR; Interventions: Device: Extra-Corporal Life Support (ECLS) | Arm Label: Standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Extra-Corporal Life Support (ECLS); Assigned to Arm(s): Extra-Corporal Life Support (ECLS)
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Device: HeartNet Ventricular Support System | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal Medical/Device Therapy | Intervention Type: DEVICE; Name: HeartNet Ventricular Support System; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: Optimal Medical/Device Therapy; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Culturally Targeted and Individually Tailored Smoking Cessation Intervention for LGBT Smokers
Brief Summary: For the approximately 4.6 million LGBT persons in the U.S., smoking rates among those living in urban areas are roughly twice that of heterosexuals. Targeted interventions have shown great promise in reducing health risk behaviors across a variety of behaviors and population groups by enhancing the relevance of the health information. The primary aim of this study is to test the efficacy of a culturally targeted group-based smoking cessation intervention (vs. a non-targeted intervention) on smoking outcomes among lesbian, gay, bisexual, and transgender (LGBT) smokers. The investigators anticipate that the culturally targeted intervention will be more effective at helping LGBT smokers to successfully stop smoking than will the non-targeted intervention.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Varenicline plus Motivational Interviewing counseling | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Varenicline without counseling | Intervention Type: OTHER; Name: Varenicline plus Motivational Interviewing counseling; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Varenicline without counseling; Assigned to Arm(s): 2
B: Arm Label: All Nations Breath of Life (ANBL); Type: EXPERIMENTAL; Interventions: Behavioral: All Nations Breath of Life (ANBL), Drug: Pharmacotherapy | Arm Label: Nontailored (NT); Type: EXPERIMENTAL; Interventions: Behavioral: Nontailored program (NT), Drug: Pharmacotherapy | Intervention Type: BEHAVIORAL; Name: All Nations Breath of Life (ANBL); Assigned to Arm(s): All Nations Breath of Life (ANBL) | Intervention Type: BEHAVIORAL; Name: Nontailored program (NT); Assigned to Arm(s): Nontailored (NT) | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): All Nations Breath of Life (ANBL), Nontailored (NT)
C: Arm Label: Culturally Targeted Cessation Program; Type: EXPERIMENTAL; Interventions: Behavioral: Culturally Targeted Cessation Program | Arm Label: Non-Targeted Cessation Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Non-Targeted Cessation Program | Intervention Type: BEHAVIORAL; Name: Culturally Targeted Cessation Program; Assigned to Arm(s): Culturally Targeted Cessation Program | Intervention Type: BEHAVIORAL; Name: Non-Targeted Cessation Program; Assigned to Arm(s): Non-Targeted Cessation Program
D: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrating Internet-supported FeetEnergy Approach in Health Education Lessons to Increase Physical Activity and Reduce Screen Time in Adolescents
Brief Summary: The purpose of this study is to find out whether an Internet-supported FeetEnergy approach and two home works integrated in three health education lessons can increase adolescents' active commuting to school and leisure-time physical activity and decrease their screen time.


Options:
A: Arm Label: Physical activity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical activity intervention group
B: Arm Label: A Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Increased physical education in primary school (daily) | Arm Label: B Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increased physical education in primary school (daily); Assigned to Arm(s): A Intervention group
C: Arm Label: Physical activity; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): Physical activity
D: Arm Label: Internet-supported FeetEnergy approach; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-supported FeetEnergy approach | Arm Label: Usual health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual health education | Intervention Type: BEHAVIORAL; Name: Internet-supported FeetEnergy approach; Assigned to Arm(s): Internet-supported FeetEnergy approach | Intervention Type: BEHAVIORAL; Name: Usual health education; Assigned to Arm(s): Usual health education

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of Nutrition and Maternal Genetics on the Programming of Development of Fetal Adipose Tissue. Search for Markers of the Obesity Risk in Early Stages of Life
Brief Summary: In the PREOBE projects it is aimed to obtain genetic and biochemical biomarkers for the programming of obesity in early stages of life. This can be achieved by studying pregnant women with normal weight, overweight, obesity and gestational diabetes, and by analyzing how these conditions could impact on fetal growth and development; the risk of obesity in the offspring during the first 3 years of life will be also assessed (genetic polymorphisms of the most recognized genes related to obesity; gene expression of placental biomarkers indicators of early programming, polyunsaturated fatty acids, immunological and pro-inflammatory markers, analysis of endogenous and exogenous lipid peroxidation, allergies \& neurodevelopmental assessment...). Moreover, the interaction of pathological maternal conditions with confounder factors that could have a role in the proposed outcomes will be also studied (maternal and child dietary intake, medical history and socioeconomic \& environmental factors).


Options:
A: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Exercise / Physical Activity | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Exercise / Physical Activity; Assigned to Arm(s): Lifestyle intervention
B: Arm Label: exercise; Type: EXPERIMENTAL; Interventions: Behavioral: specific training program | Arm Label: control; Type: ACTIVE_COMPARATOR; Interventions: Other: standard | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): control | Intervention Type: BEHAVIORAL; Name: specific training program; Assigned to Arm(s): exercise
C: Arm Label: Control group; Type: N/A; Interventions: N/A | Arm Label: Pregnant women with overweight; Type: N/A; Interventions: N/A | Arm Label: Pregnant women with obesity; Type: N/A; Interventions: N/A | Arm Label: Pregnant women with gestational diabetes; Type: N/A; Interventions: N/A
D: Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet and exercise counseling | Arm Label: Control, just measurements; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Diet and exercise counseling; Assigned to Arm(s): Lifestyle counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Daily Ingestion of Walnuts for 2 Years on Age-related Cognitive Decline and Macular Degeneration in Healthy Elderly Subjects: A Randomized, Single Blind, Dual Center, Controlled Trial
Brief Summary: This will be a systematic investigation of the role of walnuts in preventing or slowing age related cognitive decline and age related macular degeneration. 700 subjects will be recruited between 2 sites, Loma Linda University in California, USA and Hospital Clinic in Barcelona, Spain. Participants will be randomly assigned to either the walnut group or the control group for a 2 year intervention. Baseline and annual data will be collected and analyzed.


Options:
A: Arm Label: Exercise under observation; Type: EXPERIMENTAL; Interventions: Behavioral: Modified paleolithic diet and exercise under observation | Arm Label: General advice on exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Modified paleolithic diet and general advice on exercise | Intervention Type: BEHAVIORAL; Name: Modified paleolithic diet and exercise under observation; Assigned to Arm(s): Exercise under observation | Intervention Type: BEHAVIORAL; Name: Modified paleolithic diet and general advice on exercise; Assigned to Arm(s): General advice on exercise
B: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil
C: Arm Label: low fat hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dietary intervention | Arm Label: Low carbohydrate hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: dietary intervention | Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): Low carbohydrate hypocaloric diet, low fat hypocaloric diet
D: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Daily Ingestion of Walnuts for 2 Years on Age-related Cognitive Decline and Macular Degeneration in Healthy Elderly Subjects: A Randomized, Single Blind, Dual Center, Controlled Trial
Brief Summary: This will be a systematic investigation of the role of walnuts in preventing or slowing age related cognitive decline and age related macular degeneration. 700 subjects will be recruited between 2 sites, Loma Linda University in California, USA and Hospital Clinic in Barcelona, Spain. Participants will be randomly assigned to either the walnut group or the control group for a 2 year intervention. Baseline and annual data will be collected and analyzed.


Options:
A: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/ Zeaxanthin + Omega-3-FA | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/ Zeaxanthin + Omega-3-FA | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/ Zeaxanthin + Omega-3-FA; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/ Zeaxanthin + Omega-3-FA; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group
D: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo

Answer: C